EMMACE XXL
Research type
Research Study
Full title
Understanding the impact of frailty and multi-morbidity on a range of health outcomes in survivors of heart attack: The EMMACE-XXL prospective study
IRAS ID
294395
Contact name
Chris Gale
Contact email
Sponsor organisation
University of Leeds
Clinicaltrials.gov Identifier
https://bmjopen.bmj.com/content/5/6/e006256, Published EMMACE protocol; NCT01808027, EMMACE-3; NCT01819103, EMMACE-4; NCT04598048, EMMACE-XL
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
EMMACE-XXL will recruit participants who are survivors of acute coronary syndrome (a type of heart attack) to assess their health-related quality of life (HRQoL) five years or more after their heart attack. We will invite surviving participants from the EMMACE 3 and 4 studies to consent to participate in EMMACE-XXL study, they will be asked to complete a questionnaire relating to their health status, medication adherence and frailty. The questionnaire will be linked to their data collected as part of the EMMACE 3, 4 and EMMACE-XL studies including long term follow up data from NHS Digital. Separate to this application, the British Heart Foundation has funded for a download of follow up data from NHS Digital, as per the original participant consent, to be applied for and processed. The data collected from all the studies will then be analysed to understand the interplay between HRQoL, medication adherence, multi-morbidity, frailty and clinical outcomes in survivors of heart attack. This will allow targeted interventions to improve outcomes for heart attack patients. The results of the study will be published in peer reviewed journals.
REC name
London - Hampstead Research Ethics Committee
REC reference
21/PR/0810
Date of REC Opinion
8 Jul 2021
REC opinion
Further Information Favourable Opinion